KALA BIO sells $4.2M Series AAA Preferred, board control shifts to AK Holdings

KALA BIO, Inc.

Company issued 2.1M shares of Series AAA Preferred at $2/sh, raising $4.2M; each share convertible into 420 common shares (882M total potential shares).
AK Holdings appointed five directors: Avi Minkowitz, Hillel Posen, Chaim Berger, Yonatan Colman, Brendan Purdy, replacing prior board.
Stockholders approved increase in authorized common shares to 1.5B and authorized reverse stock split (1:2 to 1:100).
Six prior directors resigned (Marjan Farid, Andrew Koven, Mark Iwicki, Todd Bazemore, C. Daniel Meyers, Howard Rosen).

item 1.01 item 3.02 item 5.01 item 5.02 item 5.03 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

KALA BIO, Inc. issued 2,100,000 shares of Series AAA Preferred Stock of preferred stock to Series AAA Investors for $2.00 per share, for aggregate gross proceeds of $4.2 million.

Security: preferred stock
Shares: 2,100,000 shares of Series AAA Preferred Stock
Purchaser: Series AAA Investors
Consideration: $2.00 per share, for aggregate gross proceeds of $4.2 million

Exact text from the filing

an aggregate of 2,100,000 shares of Series AAA Preferred Stock at a price per share of Series AAA Preferred Stock equal to $2.00, for aggregate gross proceeds of $4.2 million.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

KALA BIO, Inc.: Stockholders approved an amendment to the Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock to 1,500,000,000, effective January 30, 2026 (effective 2026-01-30).

Change: charter amendment
Effective: 2026-01-30

Exact text from the filing

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As described below under Item 5.07 of this Current Report on Form 8-K, at the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation (as amended, the “ Restated Certificate of Incorporation ”), to increase the number of authorized shares of the Common Stock 1,500,000,000 shares. The increase in the number of authorized shares of Common Stock was affected pursuant to a Certificate of Amendment to the Restated Certificate of Incorporation (the “ Certificate of Amendment ”) filed with the Secretary of State of the State of Delaware on January 30, 2026, and was effective as of such date.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

KALA BIO, Inc. entered into Purchase Agreement with Series AAA Investors valued at aggregate gross proceeds of $4.2 million (effective 2026-01-30).

Action: entry
Agreement: equity purchase
Counterparty: Series AAA Investors
Value: aggregate gross proceeds of $4.2 million
Effective: 2026-01-30

Exact text from the filing

On January 30, 2026, the Company entered into that certain Securities Purchase Agreement (the “ Purchase Agreement ”) with each of the Series AAA Investors

View on SEC.gov

17 equity issuances filed in the last 30 days. Browse all equity issuances →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-26-000837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.